CpG‐Based Nanovaccines Enhance Ovarian Cancer Immune Response by Gbp2‐Mediated Remodeling of Tumor‐Associated Macrophages
Advanced Science · 2025-04 · 12 (15)
DOI: 10.1002/advs.202412881 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 22.02.2025. Verfasst von Jiaqiang Xiong und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Tumor-Associated Macrophages, Cancer Vaccines, Oligodeoxyribonucleotides. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Major Science and Technology Foundation of Hubei Province.
Abstract (Originalsprache)
CpG oligodeoxynucleotides (CpG), as an immunoadjuvant, can facilitate the transformation of tumor‐associated macrophages (TAMs)into tumoricidal M1 macrophages. However, the accumulation of free CpG in tumor tissues remains a substantial challenge. To address this, a nanovaccine (PLGA‐CpG@ID8‐M) is engineered by encapsulating CpG within PLGA using ID8 ovarian cancer cell membranes (ID8‐M). This nanovaccine demonstrates remarkable efficacy in reprogramming TAMs in ovarian cancer and significantly extends survival in ID8‐bearing mice. Notably, these findings indicate that the nanovaccine can also mitigate chemotherapy‐induced immunosuppression by increasing the proportion of M1‐like TAMs and reducing the expression of CD47 on tumor cells, thereby achieving a synergistic effect in tumor immunotherapy. Mechanistically, through transcriptome sequencing (RNA‐seq), single‐cell RNA sequencing (scRNA‐seq), and mass spectrometry‐based proteomics, it is elucidated that the nanovaccine enhances the expression of Gbp2 and promotes the recruitment of Pin1, which activates the NFκB signaling pathway, leading to the M1 polarization of TAMs. Furthermore, macrophages with elevated Gbp2 expression significantly inhibit tumor growth in both ID8 ovarian cancer and 4T1 breast cancer models. Conversely, targeting Gbp2 diminishes the antitumor efficacy of the nanovaccine in vivo. This study offers an innovative approach to immunotherapy and elucidates a novel mechanism (Gbp2‐Pin1‐NFκB pathway) for remodeling TAMs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
- Department of Gastrointestinal Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
- The Second Clinical College of Wuhan University, Wuhan, 430071, China.
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430032, China.
- Hubei Key Laboratory of Radiation Chemistry and Functional Materials, School of Nuclear Technology and Chemistry & Biology, Hubei University of Science and Technology, Xianning, 437100, China.
ORCID-Profile: Jiaqiang Xiong
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Major Science and Technology Foundation of Hubei Province
- Technology Research Project Foundation of Hubei Province
- China Postdoctoral Science Foundation
- Zhongnan Hospital of Wuhan University
- Postdoctoral Science Foundation of Hubei Province
Zitieren
APA
Xiong, J., Huang, J., Xu, H., Wu, Q., Zhao, J., Chen, Y., Fan, G., Guan, H., Xiao, R., He, Z., Wu, S., Ouyang, W., Wang, S., Zhang, L., Xia, P., Zhang, W., & Wu, M. (2025). CpG‐Based Nanovaccines Enhance Ovarian Cancer Immune Response by Gbp2‐Mediated Remodeling of Tumor‐Associated Macrophages. Advanced Science, 12(15). https://doi.org/10.1002/advs.202412881
Vancouver
Xiong J, Huang J, Xu H, Wu Q, Zhao J, Chen Y, et al. CpG‐Based Nanovaccines Enhance Ovarian Cancer Immune Response by Gbp2‐Mediated Remodeling of Tumor‐Associated Macrophages. Advanced Science. 2025;12(15). doi:10.1002/advs.202412881
BibTeX
@article{Xiong2025,
author = {Xiong, Jiaqiang and Huang, Juyuan and Xu, Hanxiao and Wu, Qiuji and Zhao, Jiahui and Chen, Yurou and Fan, Guanlan and Guan, Haotong and Xiao, Rourou and He, Zhaojin and Wu, Siqi and Ouyang, Wenliang and Wang, Shixuan and Zhang, Lu and Xia, Peng and Zhang, Wei and Wu, Meng},
title = {CpG‐Based Nanovaccines Enhance Ovarian Cancer Immune Response by Gbp2‐Mediated Remodeling of Tumor‐Associated Macrophages},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {15},
doi = {10.1002/advs.202412881}
}
EUVIMED